Bristol-Myers Squibb Company (BMY) Option Bulls Buoyed By Deal-Making

Bristol-Myers Squibb Co (BMY) will sell the rights to its cancer drug to Eli Lilly and Co (LLY)

Apr 16, 2015 at 2:24 PM
facebook twitter linkedin

Option traders have been initiating long calls over puts at a rapid-fire rate on Bristol-Myers Squibb Co (NYSE:BMY) in recent months. In fact, at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), BMY's 50-day call/put volume ratio of 5.03 ranks 1 percentage point from a 52-week peak.

Echoing this call-skewed bias is the security's Schaeffer's put/call open interest ratio (SOIR) of 0.41, which rests lower than 85% of all similar readings taken in the past year. Simply stated, short-term speculators have been more call-heavy toward BMY just 15% of the time during the last 12 months.

In today's session, calls are trading at 1.2 times what's typically seen at this point in the day, and are outpacing puts by an 8-to-1 ratio. Per the equity's 30-day at-the-money implied volatility -- which is up 3.8% at 24.4% -- short-term contracts are seeing increased attention. Drilling down, the ISE has confirmed buy-to-open activity at BMY's weekly 4/24 64-strike call, meaning speculators are betting on a breakout above $64 by next Friday's close, when the series expires.

On the charts, Bristol-Myers Squibb Co (NYSE:BMY) has been put in a strong performance over the past year, up 28.8% to trade at $63.72. Off the charts, the biopharmaceutical firm has been making a string of deals of late, including today's announcement that it will shift full North American commercialization rights (subscription required) of its cancer drug, Erbitux, to Eli Lilly and Co (NYSE:LLY).




These investors are using the market's volatility to their advantage and scoring triple-digit gains on many of their trades.

Even in today's sideways bear market, this trading strategy has continued to provide consistency and profitability to a small group of investors. By using this approach, these traders are removing directional risk and still hitting triple-digit returns. If you want access to this strategy, and lower risk with higher returns sounds good to you, then don't wait another minute.

Join us now to receive our next trades the moment they come out!


Common mistakes options traders make


Special Offers from Schaeffer's Trading Partners